Message from our CEO

Martin Willner, CEO

“Fresenius Kabi Canada’s portfolio comprises of a wide range of IV generics, complex biopharmaceuticals, clinical nutrition and a range of medical devices including infusion pumps, apheresis machines and cell therapy devices. The essential nature and breadth of our portfolio means that Fresenius Kabi Canada plays an essential role in putting lifesaving medicines and technologies in the hands of people who help patients every day. Fresenius Kabi Canada is part of a global company employing more than 40,000 people, all dedicated to fulfilling our corporate mission of ‘Caring for Life’”

Martin Willner assumed the role of CEO at Fresenius Kabi Canada on July 1st, 2023. With over three decades of experience within the pharmaceutical and medical device industry, Martin brings a wealth of knowledge and expertise to this leadership position. His journey at Fresenius Kabi Canada began in 2007, and over the years, he has demonstrated his commitment and dedication to the organization. Martin's proven track record and extensive experience in senior commercial roles in Germany and the UK make him a natural fit to lead the Canadian branch of this global healthcare company.

His educational background further strengthens his qualifications for this role. He holds an MBA, which equips him with strategic and business acumen, as well as a bachelor's degree in applied and human biology. This combination of scientific and business knowledge positions him well to understand the intricacies of the healthcare industry and drive the growth and success of Fresenius Kabi Canada.